First Phase III Results Keep Pfizer's Abrocitinib Among JAK Leaders In Atopic Dermatitis

 
• By Mandy Jackson
  
Evening scene asphalt international race track with starting or end line, digital imaging recomposition background.
JAK inhbitors are racing to the finish in atopic dermatitis. • Source: Shutterstock

More from Clinical Trials

More from R&D